Table 2.
Types of cancer therapy in the cohort
| Type of cancer treatment | n | % |
|---|---|---|
| Antibody-drug conjugate | 7 | 4% |
| Anti-CD20 antibody therapy | 23 | 12% |
| Anti-CD38 antibody therapy | 10 | 5% |
| Anti-HER2 antibody therapy | 16 | 8% |
| AR-targeted therapy | 6 | 3% |
| BCL-2 inhibitor | 7 | 4% |
| BTK inhibitor | 2 | 1% |
| CAR-T cell therapy | 3 | 2% |
| CDK4/6 inhibitors | 5 | 3% |
| Chemotherapy | 112 | 56% |
| Clinical trial (experimental therapy) | 7 | 4% |
| EGFR inhibitor | 1 | 1% |
| Hormonal therapy (ADT, OFS, and AI) | 47 | 24% |
| Immune checkpoint inhibitor | 31 | 16% |
| Immunomodulator | 22 | 11% |
| mTOR inhibitors | 2 | 1% |
| No treatment | 11 | 6% |
| Protease inhibitor | 19 | 10% |
| Radiation | 55 | 28% |
| Stem cell transplant | 26 | 13% |
| Supportive care | 6 | 3% |
| Surgery | 59 | 30% |
| TGFβ inhibitor | 3 | 2% |
| Tyrosine kinase inhibitor | 9 | 5% |
| VEGF inhibitor | 7 | 4% |
AR, androgen receptor; BCL-2, B cell lymphoma 2; BTK, Bruton’s tyrosine kinase; EGFR, epidermal growth factor receptor; ADT, androgen deprivation therapy; OFS, ovarian function suppression; AI, aromatase inhibitors; mTOR, mammalian target of rapamycin; TGFβ, transforming growth factor β; VEGF, vascular endothelial growth factor.